Intravenous immunoglobulin treatment in multiple sclerosis

A. Achiron, I. R. Cohen, O. Lider, E. Melamed

Research output: Contribution to journalArticlepeer-review


Multiple sclerosis (MS) is the most common central nervous system demyelinating disease. The disease can manifest itself clinically in a relapsing-remitting, chronic-progressive, or combined form. Meanwhile, intravenous immunoglobulin (IVIg) has been used in recent years to treat disorders of immune regulation such as idiophatic thrombocytoponic purpura, autoimmune hymolytic anemia, rheumatoid arthritis and many others. Thus, it was hypothesized that if MS pathogens indeed involved impaired immune mechanisms, administration of IVIg may be beneficial. This paper evaluate the effects of IVIg in MS by treating 10 relapsing-remitting MS patients with repeated infusions of IgG, once every to months for 1 year. Furthermore, the long-term clinical effect of IVIg treatment in relapsing-remitting MS patient for 3 years is evaluated.

Original languageEnglish
Pages (from-to)7-9
Number of pages3
JournalIsrael Journal of Medical Sciences
Issue number1
StatePublished - Jan 1995
Externally publishedYes


  • Autoimmunity
  • Intravenous immunoglobulin
  • Multiple sclerosis


Dive into the research topics of 'Intravenous immunoglobulin treatment in multiple sclerosis'. Together they form a unique fingerprint.

Cite this